DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults. These aggressive tumours are characterised by inherent treatment resistance and disease progression, contributing to ~ 190 000 brain tumour‐related deaths globally each year. Current therapeutic interventions consi...
Main Authors: | Ola Rominiyi, Spencer J. Collis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13020 |
Similar Items
-
Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity
by: Callum G. Jones, et al.
Published: (2024-02-01) -
Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma
by: Natasha Carmell, et al.
Published: (2021-02-01) -
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma
by: Emeline Tabouret, et al.
Published: (2020-07-01) -
Electrotherapies for Glioblastoma
by: Elise P. W. Jenkins, et al.
Published: (2021-09-01) -
Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology
by: Yitzhak Zimmer, et al.
Published: (2020-10-01)